Scintica and CLECELL Announce Partnership for Exclusive Market Entry of Bioprinting Systems in North America and Europe

[July, 2025]

Scintica, a leading provider of advanced preclinical and biomedical research technologies, is proud to announce an exclusive partnership with CLECELL, a South Korea–based bioprinting and tissue engineering company. Through this agreement, Scintica will serve as CLECELL’s exclusive go-to-market partner for its bioprinting systems across North America and Europe.

CLECELL’s proprietary 3D bioprinting portfolio includes four platforms: U-FAB MASTER, ACTIVO, NOVO, and CLIBOT. Developed in collaboration with research teams at Harvard Medical School, these systems are designed for diverse applications in tissue engineering, regenerative medicine, and drug screening. CLECELL’s flagship product U-FAB ACTIVO—which has received domestic Class 1 approval as an in vitro diagnostic medical device—stands out for its ability to print both low- and high-viscosity bioinks with precision.

CLECELL’s bioprinters use a droplet-based method for accurate deposition of low-viscosity bioinks, including cells. Post-printing, five cross-linking strategies—pH-responsive, enzymatic, chemical, UV LED, and heat-responsive—ensure structural stability of the printed tissues. This advanced capability supports the creation of personalized tissue models, such as artificial skin, cancer organoids, and stem cell-based constructs.

“Our in-house team of scientists and experts are eager to be able to introduce this exciting technology to end users to develop tissue engineering therapies and translate that to patients”. Said Blair Poetschke, President of Scintica.

Dr. Niloufar Khosravi, Senior Product Manager at Scintica added “We’re thrilled to partner with CLECELL to bring their technology to the western market. CLECELL product portfolio enables researchers and clinicians to accelerate the development of functional and living tissues for transplantation. In addition to that, in line with the growing momentum behind the FDA Modernization Act and EURL ECVAM initiatives, such alternatives methods reduce reliance on costly and often unreliable preclinical models—enhancing early-stage decision-making and accelerating the development of safer and more effective therapies.”

Yunil Kook, Executive Vice President of CLECELL, stated, ” This collaboration marks a significant step in Clecell’s expansion into global markets, including the United States and Europe. 3D bioprinting technology possesses unlimited potential to evolve into vital medical devices, research equipment, and clinical simulation platforms. We are committed to becoming a key partner in the global life science industry through our tissue simulation technology, enabling accurate diagnosis and advanced treatment.”Sen